The report “Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90), by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020”, this report studies the global nuclear medicine/radiopharmaceuticals market for the forecast period of 2015 to 2020. This market is expected to reach $6.96 Billion by 2020 from $4.50 Billion in 2015, at a CAGR of 9.1% during the forecast period.
Browse 113 market data tables and 55 figures spread through 230 pages and in-depth TOC on “Nuclear Medicine/Radiopharmaceuticals Market"
Early buyers will receive 10% customization on this report.
Nuclear medicine/radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation, used in the nuclear imaging field to diagnose and treat diseases. The radiopharmaceuticals market is bifurcated into diagnostics and therapeutics segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET; whereas, radiopharmaceuticals in the therapeutics market are categorized as beta emitters, brachytherapy isotopes, and alpha emitters.
The global radiopharmaceuticals market is segmented on the basis of type, application, and region. Based on type, the nuclear medicine market is categorized into diagnostics and therapeutics segments. In 2014, the diagnostics segment accounted for the largest share of the nuclear medicine market. The diagnostics segment is further segmented into SPECT and PET. In 2014, the SPECT segment accounted for the largest share of the radiopharmaceuticals diagnostics market. The therapeutics segment is further segmented into beta emitters, alpha emitters, and brachytherapy isotopes. In 2014, the beta emitters segment accounted for the largest share of the radiopharmaceuticals therapeutics market.
Ask For The PDF Brochure Of This Report: http://www.marketsandmarkets.com/pdfdownload.asp?id=417
Based on applications, the nuclear medicine market is segmented into diagnostics (SPECT and PET) and therapeutics applications. In 2014, the diagnostics segment accounted for the largest share of the nuclear medicine market.
Factors such as advances in radiotracers, alpha radio immunotherapy-based targeted cancer treatment, and increasing number of patients with cancer and cardiovascular aliments are driving the growth of this market. Moreover, potential radioisotopes in the pipeline, high demand from emerging countries, and advances in neurological applications are likely to create huge opportunities for this market in the coming years. However, factors such as shorter half-life of radiopharmaceuticals, stringent regulatory guidelines, and competition from conventional diagnostic procedures are hindering the growth of this market.
On the basis of regions, the radiopharmaceuticals market is classified into North America, Europe, Asia-Pacific, and the Rest of the World (RoW)..
The global radiopharmaceuticals market is expected to reach $6.96 Billion by 2020 from $4.50 Billion in 2015, growing at a CAGR of 9.1% from 2015 to 2020. The market is dominated by North America, followed by Asia-Pacific, Europe, and the Rest of the World (RoW) regions. The Asia-Pacific region is expected to grow at the fastest rate during the forecast period.
Get The Sample Copy Of This Report:
Some of the major players in the global nuclear medicine market include Cardinal Health, Inc. (U.S.), GE Healthcare (U.K.), Bracco Imaging S.p.A (Italy), Eczacibasi-Monrol Nuclear Products (Turkey), Nordion, Inc. (Canada), Advanced Accelerator Applications S.A. (France), Bayer Healthcare (Germany), Lantheus Medical Imaging, Inc. (U.S.), IBA Molecular Imaging (Belgium), and Mallinckrodt plc (Ireland).
Browse Related Reports:
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017.
North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017.
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Subscribe Reports from Healthcare Domain @ http://www.marketsandmarkets.com/Subscription.html
Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune – 411013,
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/pharmaceuticalsConnect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets